Clinical Trial Update: Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab in the Parent Study R5458-668-ALG-2219 (NCT06369467)

View source ↗

Summary

Expanded Access Program update for dupilumab in adults with severe IgE-mediated food allergy; the program is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Food Allergy

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Food Allergy | Status: NO_LONGER_AVAILABLE